Citizens JMP raised the firm’s price target on Savara (SVRA) to $11 from $8 and keeps an Outperform rating on the shares. The firm’s pulmonologist survey indicates high demand for Molbreevi. 60% of those surveyed want to use Molbreevi, which should translate to blockbuster sales, the analyst tells investors in a research note. Citizens says Savara remains on track to resubmit its application for Molbreevi in December.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara promotes Wasfi to Chief Medical Officer
- Savara initiated with an Outperform at LifeSci Capital
- Savara’s MOLBREEVI: A Promising Solution for Autoimmune Pulmonary Alveolar Proteinosis with Blockbuster Potential
- Savara present results from Phase 3 IMPALA-2 Molgramostim study
- Savara management to meet virtually with Piper Sandler